期刊文献+

自体动静脉内瘘术后使用时机对内瘘功能的影响 被引量:2

How to effect on its function of what time in using arteriovenous fistula for hemodialysis
下载PDF
导出
摘要 目的根据血液透析患者的动静脉内瘘术后成熟与否,分析内瘘使用时间与其并发症发生率的关系。方法取本中心5年来内瘘透析患者,整理比较使用内瘘透析治疗前,患者的一般项目和内瘘局部情况,选出条件基本趋同的96例,按内瘘成熟标准选取59例为成熟组;其余未达标的37例为成熟不良组;分别观察从第2周、4周、6周、8周开始使用,比较分析两组在不同时间段并发症发生率。结果内瘘使用前两组一般项目检验分析,瘘口血流量统计学检验差异有显著性。两组对比从第4、6、8周三种并发症发生率均呈下降趋势,成熟组发生率第4、6周明显低于不良组,比较差异有显著性P〈0.05;第8周两组比较差异无显著性P〉0.05。结论内瘘并发症多发生于术后6周内,以闭塞引起的严重并发症多出现于2~4周,内瘘使用应避开这一高危期,最好最好是在术后6~8周。 Objective To analyzed the two facts between arteriovenous fistula' s using time and its syndrome rate. Methods we selected ninety - six with arteriovenous fistula Uraemia patients from our hemopurifying - centre, they were divided into two groups according to maturation standard of native internal AVF : AVF maturation garoup 59 cases, non -maturation garoup 31 cases ,the rate of aneurism ,stenosis and occlusion of AVF were observed in two groups at the beginning of using AVF for hemodialysis : post - surgery the fourth, sixth, eighth week. Results The rate of AVF - sydrom at the fourth ,sixth week maturation garoup was obviously lower than that of non - maturation garoup P 〈 O. 05, the eighth week two groups were not different in AVF - sydrom ( P 〉 0.05 ). Conclusions The best using time of IA- VF is at the 6th - 8th week after AVF - sugery.
作者 王辉
出处 《医学信息(手术学分册)》 2008年第8期718-720,共3页 Medical Information Operations Sciences Fascicule
关键词 尿毒症 动静脉内瘘 血液透析 并发症 uraemia arteriovenous fistula hemodialysis aneurism stenosis occlusion
  • 相关文献

参考文献2

二级参考文献18

  • 1Joseph A, Vassalotti, Abrigail Falk, et al. The Multidisciplinary Approach to 1.2.4[J]. Journal of Medicine,2004,71(2):94-102.
  • 2Sukbatme VP. Vascular access stenosis : Prospects for prevention and therapy[J]. Kidney Int,1996,49(6): 1161-1174.
  • 3Windus DW. Permanent vascular access: a nephrologist's view[J]. Am J Kidney Dis,1993,21(6):457-471.
  • 4De Marchi S, Ceccin E, Falleti E, et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients[J]. J Am Soc Nephrol,1997, 8(7) :1147-1156.
  • 5Churchill DN, Muirhead N, Goldstein M, et al. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin [J ]. J Am Soc Nephrol, 1994,4(10) : 1809-1813.
  • 6Crowther MA, Clase CM, Margetts P J, et al. Low-intensity warfarin is ineffctive for the prevention of PTFE graft failure in patients on hemodialysis :a randomized controlled trial[J]. J Am Soc Nephro1,2002,13(9) :2331-2337.
  • 7Kaufan JS, O'connor TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis [J ]. J Am Soc Nephrol, 2003, 14 (9) :2313-2323.
  • 8Vassalotti JA, Kalk A, Cohl ED, et al. Obese and non-obese hemodialysis patients have a similar prevalence of functioning arteriovenous fistula using pre-operative mapping [J]. Clin Nephrol,2002,58(3) : 211-214.
  • 9Ort Y,Karzets A,katz M,et al.Hemodialy sis arteriovenousaccess a prospective hemodialysis evaluation[J].Nephrol Dial Ttansplant,1996,11[suppl]:94-97.
  • 10Kingdon EJ,Holt SG,Davar J,et al.Atrial thrombus and central venous dialysis calheters[J].Am J Kidney Dis,2001,38(3):631-639.

共引文献58

同被引文献8

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部